+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Onychomycosis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830096
  • Drug Pipelines
  • Region: Global
  • 59 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Almirall SA
  • Hallux Inc
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • MORE
High levels of pipeline activity are being observed in Onychomycosis treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Acea Biotech Inc, Almirall SA, Blueberry Therapeutics Ltd, Exodos Life Sciences Limited Partnership, Hallux Inc and others.

A Significant contribution to the Onychomycosis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Onychomycosis pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Onychomycosis condition and increased access to investments is encouraging growth of Onychomycosis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Onychomycosis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Onychomycosis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Onychomycosis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Onychomycosis. Further, orphan drug status, fast track designation, grants awarded and other special status for Onychomycosis pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Onychomycosis pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Onychomycosis Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Onychomycosis drugs
  • Late phase: Phase 3 and in-approval Onychomycosis drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Onychomycosis therapeutic treatment activities
Details for each Onychomycosis drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Onychomycosis therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Almirall SA
  • Hallux Inc
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Onychomycosis (Nail fungus)- Disease Overview
2.2 Onychomycosis (Nail fungus)- Pipeline Snapshot
2.3 Onychomycosis (Nail fungus)- Pipeline Drugs by Phase
2.4 Onychomycosis (Nail fungus)- Pipeline Drugs by Company
2.5 Onychomycosis (Nail fungus)- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Acea Biotech Inc Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.2 Almirall SA Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.3 Blueberry Therapeutics Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.4 Exodos Life Sciences Limited Partnership Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.5 Hallux Inc Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.6 Hexima Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.7 Kaken Pharmaceutical Co Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.8 Meiji Seika Pharma Co Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.9 Moberg Pharma AB Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.10 Mycovia Pharmaceuticals Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.11 NAL Pharmaceuticals Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.12 Novabiotics Ltd Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.13 Novan Inc Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.14 Sanotize Research And Development Corp Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.15 Turn Therapeutics Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019
3.16 Viamet Pharmaceuticals Inc Onychomycosis (Nail fungus) Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Onychomycosis (Nail fungus)- Phase 1 Drug Details
4.2 Onychomycosis (Nail fungus)- Phase 1 Drug Overview
4.3 Onychomycosis (Nail fungus)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Onychomycosis (Nail fungus)- Phase 2 Drug Details
5.2 Onychomycosis (Nail fungus)- Phase 2 Drug Overview
5.3 Onychomycosis (Nail fungus)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Onychomycosis (Nail fungus)- Phase 3 Drug Details
6.2 Onychomycosis (Nail fungus)- Phase 3 Drug Overview
6.3 Onychomycosis (Nail fungus)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Onychomycosis (Nail fungus)- Pre-clinical Phase Drug Details
7.2 Onychomycosis (Nail fungus)- Pre-clinical Phase Drug Overview
7.3 Onychomycosis (Nail fungus)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acea Biotech Inc
  • Almirall SA
  • Blueberry Therapeutics Ltd
  • Exodos Life Sciences Limited Partnership
  • Hallux Inc
  • Hexima Ltd
  • Kaken Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Sanotize Research And Development Corp
  • Turn Therapeutics
  • Viamet Pharmaceuticals Inc
  • Mycovia Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll